Objective To explore the clinical application and safety of post operation adjuvant chemotherapy in the patients with colorectal carcinoma undergoing radical resection surgery. Methods Clinical data of 110 patients with stage Ⅲ colorectal carcinoma undergoing radical resection surgery were retrospectively analyzed. 110 patients were divided into adjuvant chemotherapy group (62 cases) and single operation group (48 cases). 3 year recurrence rate, disease free survival time and adverse reactions of the two groups were analyzed. Results 3-year recurrence rate of adjuvant chemotherapy group was lower than thai of single operation group (24-2% vs 35-4%), there was a significant difference (P ＜ 0-05). Disease-free survival time in adjuvant chemotherapy group and single operation group was 18 months and 12 months respectively, there was a significant difference (P ＜ 0.05). Anorexia, nausea/vomiting, alopecie and pigmentation were the main adverse reactions in adjuvant chemotherapy group. Most of the adverse reactions were tolerable for the patients. Conclusion Stage Ⅲ colorectal carcinoma undergoing radical resection surgery can greatly improve disease-free survival time of the patients, the patients can endure most of adverse reactions.%目的 探讨Ⅲ期结肠癌患者根治术后行辅助化疗的临床疗效及安全性.方法 回顾性分析110例Ⅲ期行结肠癌根治术患者的临床资料,其中术后行辅助化疗者62例,单纯手术者48例.比较两组患者3年复发转移率、无病生存时间及辅助化疗组的不良反应.结果 辅助化疗组3年复发转移率显著低于对照组(24.2% vs 35.4%),差异有统计学意义(P < 0.05);辅助化疗组与单纯手术组无病生存时间分别为18个月和12个月,两组比较,差异有统计学意义(P < 0.05).食欲不振、恶心呕吐、脱发及色素沉着为辅助化疗组最常见的不良反应,但患者大都可耐受.结论 Ⅲ期结肠癌患者根治术后行辅助化疗可显著提高患者无病生存时间,不良反应大都可耐受.
展开▼
